BioDir 研究关注：Gene Therapy ETX101 Improves Seizures and Neurodevelopment in Dravet Syndrome in Phase I/II
New Phase I/II POLARIS data presented at the ASGCT Presidential Symposium show ETX101 delivering durable seizure reduction and early neurode...
## 事件概览
New Phase I/II POLARIS data presented at the ASGCT Presidential Symposium show ETX101 delivering durable seizure reduction and early neurode...
## 核心信息
New Phase I/II POLARIS data presented at the ASGCT Presidential Symposium show ETX101 delivering durable seizure reduction and early neurodevelopmental gains in children with SCN1A+ Dravet syndrome, highlighting the promise of targeted gene regulation therapy. The post Gene Therapy ETX101 Improves Seizures and Neurodevelopment in Dravet Syndrome in Phase I/II appeared first on GEN - Genetic Engineering and Biotechnology News .
## 为什么值得关注
这条内容与 development 相关，可能影响科研选题、技术趋势判断或产业观察。BioDir 已根据来源、摘要长度、主题词和潜在影响给出 47 分的候选评分。
## 发布提示
发布前应核对原文链接、研究对象、样本规模、方法限制和结论边界。若来源为 bioRxiv 或 medRxiv，应明确标注其为预印本，尚未经过同行评议。